These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23731224)

  • 1. Short communication: Use of raltegravir in late-presenting HIV-infected pregnant women.
    Nóbrega I; Travassos AG; Haguihara T; Amorim F; Brites C
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1451-4. PubMed ID: 23731224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Factors associated with virological response in women receiving highly-active antiretroviral prophylaxis for HIV-1 mother-to-child transmission].
    Palacios R; Senise JF; Vaz MJ; Castelo A
    Enferm Infecc Microbiol Clin; 2008; 26(7):411-5. PubMed ID: 18842235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 viremia during the first 28 weeks of pregnancy is not associated with mother-to-child transmission.
    Senise JF; Palacios R; Tanno ZN; Lunardi L; Waghabi GR; Vaz MJ; Diaz RS; Castelo A
    Braz J Infect Dis; 2006 Aug; 10(4):259-63. PubMed ID: 17293908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa.
    Myer L; Phillips TK; McIntyre JA; Hsiao NY; Petro G; Zerbe A; Ramjith J; Bekker LG; Abrams EJ
    HIV Med; 2017 Feb; 18(2):80-88. PubMed ID: 27353189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women.
    Brites C; Nóbrega I; Luz E; Travassos AG; Lorenzo C; Netto EM
    HIV Clin Trials; 2018 Jun; 19(3):94-100. PubMed ID: 29629852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy.
    Westling K; Pettersson K; Kaldma A; Navér L
    AIDS Patient Care STDS; 2012 Dec; 26(12):714-7. PubMed ID: 23101466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review.
    De Hoffer L; Di Biagio A; Bruzzone B; Sticchi L; Prinapori R; Gerbaldo D; Gotta C; Viscoli C
    J Chemother; 2013 Jun; 25(3):181-3. PubMed ID: 23783144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal HIV-1 DNA load and mother-to-child transmission.
    Arvold ND; Ngo-Giang-Huong N; McIntosh K; Suraseranivong V; Warachit B; Piyaworawong S; Changchit T; Lallemant M; Jourdain G;
    AIDS Patient Care STDS; 2007 Sep; 21(9):638-43. PubMed ID: 17919090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of antiretroviral regimen on viral suppression among pregnant women living with HIV in Brazil.
    Pascom ARP; Fonseca FF; Pinho RGG; Perini FB; Pereira G; Avelino-Silva VI
    Int J STD AIDS; 2020 Aug; 31(9):903-910. PubMed ID: 32702281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
    João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
    Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-level risk factors for vertical transmission of HIV in the national prevention of mother-to-child transmission programme in South Africa: An ecological analysis.
    Moyo F; Haeri Mazanderani A; Sherman GG; Kufa T
    S Afr Med J; 2022 Mar; 112(3):219-226. PubMed ID: 35380525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort.
    Warszawski J; Tubiana R; Le Chenadec J; Blanche S; Teglas JP; Dollfus C; Faye A; Burgard M; Rouzioux C; Mandelbrot L;
    AIDS; 2008 Jan; 22(2):289-99. PubMed ID: 18097232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.
    Blonk MI; Colbers AP; Hidalgo-Tenorio C; Kabeya K; Weizsäcker K; Haberl AE; Moltó J; Hawkins DA; van der Ende ME; Gingelmaier A; Taylor GP; Ivanovic J; Giaquinto C; Burger DM; ;
    Clin Infect Dis; 2015 Sep; 61(5):809-16. PubMed ID: 25944344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with viral load suppression in HIV-infected pregnant women in Rio de Janeiro, Brazil.
    Joao EC; Gouvêa MI; Menezes JA; Sidi LC; Cruz ML; Berardo PT; Ceci L; Cardoso CA; Teixeira Mde L; Calvet GA; Matos HJ
    Int J STD AIDS; 2012 Jan; 23(1):44-7. PubMed ID: 22362687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
    Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
    PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical Review: Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy.
    Maliakkal A; Walmsley S; Tseng A
    J Acquir Immune Defic Syndr; 2016 Jun; 72(2):153-61. PubMed ID: 27183177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial.
    Frenkel LM; Morrison RL; Fuller TL; Gouvêa MI; Benamor Teixeira ML; Coombs RW; Shapiro DE; Mirochnick M; Hennessey R; Whitson K; Chakhtoura N; João EC
    J Acquir Immune Defic Syndr; 2021 Dec; 88(4):361-365. PubMed ID: 34369908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Three Antiretroviral Regimens Initiated during Pregnancy: Clinical Experience in Rio de Janeiro.
    Benamor Teixeira ML; Fuller TL; Fragoso Da Silveira Gouvêa MI; Santos Cruz ML; Ceci L; Pinheiro Lattanzi F; Sidi LC; Mendes-Silva W; Nielsen-Saines K; Joao EC
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33020151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
    Lennox JL; Dejesus E; Berger DS; Lazzarin A; Pollard RB; Ramalho Madruga JV; Zhao J; Wan H; Gilbert CL; Teppler H; Rodgers AJ; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Sklar P;
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):39-48. PubMed ID: 20404738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.